title: A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.
abstract: We studied the efficacy of two different doses of ganciclovir to prevent cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. We randomly assigned allogeneic HSCT recipients who had CMV infection to receive preemptive ganciclovir therapy with or without induction phase (5 mg/kg twice daily for 1 week). Thirty-two and thirty-six patients were randomized to the standard and the low-dose therapy group, respectively. The median time to CMV antigenemia or viremia clearance was 7 days (3-25 days) in the standard therapy group versus 11 days (3-69 days) in the low-dose therapy group (P = 0.540). The incidence of CMV disease was similar between the two groups (P = 0.366). The Kaplan-Meier estimate of event-free survival by day 180 after HSCT was 76.2% in the standard therapy group versus 66.7% in the low-dose therapy group (P = 0.590). Severe neutropenia (<0.5 x 10(9)/L) was observed in four (12.5%) patients in the standard therapy group versus two (5.6%) patients in the low-dose therapy group (P = 0.314). This study suggests that a low-dose ganciclovir preemptive therapy can be as effective as the standard-dose ganciclovir preemptive therapy for the prevention of CMV disease in allogeneic HSCT recipients.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
authors.forename: Seung Tae
authors.initials: ST
authors.lastname: Kim
authors.forename: Mark H
authors.initials: MH
authors.lastname: Lee
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Dong Hwan
authors.initials: DH
authors.lastname: Kim
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Jang
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Chul Won
authors.initials: CW
authors.lastname: Jung
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir
references.citation: Blood. 2002 Feb 15;99(4):1159-64
references.pmid: 11830461
references.citation: N Engl J Med. 1991 Dec 5;325(23):1601-7
references.pmid: 1658652
references.citation: Blood. 1997 Sep 15;90(6):2502-8
references.pmid: 9310503
references.citation: Rev Infect Dis. 1982 Nov-Dec;4(6):1119-32
references.pmid: 6296961
references.citation: Blood. 1996 Nov 15;88(10):4063-71
references.pmid: 8916975
references.citation: Ann Intern Med. 1993 Feb 1;118(3):173-8
references.pmid: 8380242
references.citation: Bone Marrow Transplant. 2001 Feb;27(4):437-44
references.pmid: 11313674
references.citation: Ann Intern Med. 1986 Feb;104(2):168-75
references.pmid: 3511812
references.citation: Transplantation. 1997 Jul 15;64(1):108-13
references.pmid: 9233710
references.citation: Bone Marrow Transplant. 2002 May;29(9):777-82
references.pmid: 12040476
references.citation: Bone Marrow Transplant. 2003 Oct;32(7):703-7
references.pmid: 13130318
references.citation: Antimicrob Agents Chemother. 1987 Mar;31(3):452-4
references.pmid: 3495235
references.citation: Clin Infect Dis. 2002 Oct 15;35(8):999-1004
references.pmid: 12355388
references.citation: Biol Blood Marrow Transplant. 2009 Jun;15(6):679-85
references.pmid: 19450752